NeOnc Provides Business Update and Reports Q4 2025 Financial Results
NeOnc Technologies Holdings, Inc. announced their Q4 and full-year 2025 financial results, highlighted by clinical progress in their CNS cancer drug candidates NEO100 and NEO212, successful enrollment in pivotal trials, strategic Middle East expansion, leadership appointments, and a $10 million PIPE financing that strengthens their balance sheet. E…